|
Gene by Gene acquires Arpeggi Inc.
08-07-2013
EDIT CONNECT
SHARING OPTIONS:
HOUSTON—Gene by Gene Ltd. has announced the acquisition of
Arpeggi Inc., which develops solutions for genome sequencing, data management
and computational analysis. Arpeggi is backed by StartUp Health and GE. Once
the transaction is complete, the combined company will be able to offer a suite
of affordable genetics testing and diagnostics services for consumers,
researchers and healthcare providers. No financial details for the transaction
were made available.
"The acquisition of Arpeggi's technology and world-class
team of data and technology experts will enable us to accelerate Gene by Gene's
plan to make next-generation DNA sequencing and clinical genomics accessible
and affordable to all," said Max Blankfeld, managing partner of Gene by Gene,
in a press release. "We are on a mission to transform healthcare by
dramatically speeding up the process, and reducing the costs, of genetic tests,
which today are often far too expensive for the average customer."
As a result of this acquisition, the entire Arpeggi team and
the company's technology platform will be incorporated into Gene by Gene, with
Arpeggi's founders joining the Gene by Gene management team. Nir Leibovich of
Arpeggi has been named chief business officer for Gene by Gene, with Jason Wang
to serve as chief technology officer and David Mittelman, Ph.D., taking up the
position of chief scientific officer. Gene by Gene offers DNA testing to answer
paternity questions, determine ancestry, identify genetic disorders or
inherited diseases and for research.
"The deluge of data generated from genomic testing, and the
ability to store, analyze and interpret it efficiently, has been a bottleneck
for organizations focused on large-scale sequencing," Rafael Torres, senior
managing director at GE Ventures-Healthcare, commented in a statement.
"Arpeggi's solution provides an infrastructure that helps human genomic and
bioinformatics companies get the most out of their data. We're proud to have
Arpeggi involved with our Entrepreneurship Program with StartUp Health and
cannot wait to see them further advance DNA testing through the marriage of
science and technology."
Arpeggi, which debuted in 2012, released a new platform in
April: GCAT- Genome Comparison and Analytic Testing, a free, community-driven
platform for evaluating the performance of next-generation sequencing data
analysis methods. Arpeggi was chosen as one of 14 startups to join the StartUp
Health and GE Entrepreneurship Program this year.
"We are thrilled by the acquisition of Arpeggi and excited
to continue to help Gene by Gene on its mission to lead the rapidly advancing
genetics testing and sequencing market," Unity Stoakes, co-founder and
president of StartUp Health, said in a press release. "This acquisition
represents a significant combination of technologies, expertise and
infrastructure that we believe will make an important impact on the future of
the genomics sector and how many people have access to these innovations."
SOURCE: Gene by Gene press release
Code: E08071301 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|